ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Minerva Neurosciences (NERV)
Minerva Neurosciences stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$2.22▲ +0.91%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Minerva Neurosciences in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Minerva Neurosciences
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Minerva Neurosciences a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $1.88 and $2.50; in 9 out of 10, between $1.46 and $3.23. Estimated annual volatility is 83%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $157M
- 52-week high
- $8.80
- 52-week low
- $2.18
- Revenue (12 months)
- $0.0M
- Earnings growth (YoY)
- -18,350.0%
- Return on equity
- 208.5%
- Free cash flow (12 months)
- $-8.9M
- Beta
- -0.10
What this means
ATLAS does not publish a fair value for NERV right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks NERV has traded between $2.18 and $8.80. Today it is 74.8% below that high and 2% above its low.
Its beta is -0.10: it tends to move less than the market.
About the company
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders.
Want to see everything about Minerva Neurosciences?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Minerva Neurosciences do?
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders.
What is the chance NERV goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, NERV ends the month between $1.88 and $2.50.
How big is Minerva Neurosciences and what is its P/E ratio?
Minerva Neurosciences's market capitalization is $157M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is NERV?
ATLAS estimates annual volatility at 83%. In a typical month, half of the outcomes end between $1.88 and $2.50.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer